Lexaria Bioscience to evaluate impact of DehydraTECH on GLP-1 drugs

Lexaria Bioscience announces its intention to launch new human and animal studies to examine DehydraTECH-processed glucagon-like peptide-1 drugs such as, but not limited to, semaglutide sold under Novo Nordisk’s brand names Ozempic, Wegovy and Rybelsus, for purposes of improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Through these studies, Lexaria hopes to achieve superior pharmacokinetic performance using DehydraTECH-powered GLP-1 drugs which could enable drug delivery via oral capsule at lower costs than current injectables, with reduced side effects and enhanced health benefits. This is a significant expansion of Lexaria’s ongoing and planned diabetes study program to examine its patented DehydraTECH-CBD for diabetes control in humans. The Company now intends to evaluate this alongside and together with DehydraTECH-processed GLP-1 agents. Program design has already commenced, and initial study work will begin as soon as possible.